DLA Piper advises Heron Therapeutics on sale of substantially all assets to CorMedix...
11 November 2026 .2 minute read
DLA Piper advises underwriters in Strive’s US$630 million preferred stock initial public...
27 October 2026 .2 minute read
DealCatalyst Fund Finance West 2026: Key takeaways
21 October 2026 .5 minute read